Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, enabling them to live their lives more fully.

Jazz Pharmaceuticals

Acura Pharmaceuticals is an innovative drug delivery company focused on developing technologies and products to address safe use of medications, particularly in the area of abuse-deterrent formulations for opioids and pseudoephedrine.

Acura Pharmaceuticals, Inc.

Collegium Advisors is an independent, full-service corporate finance and valuation advisor. The company offers services in Corporate Finance, Valuation Advisory, and Fixed Asset Solutions, including Mergers and Acquisitions, Due Diligence, Restructuring, Intangible Asset Valuation, Business Valuation, Accounting Valuation, and Insurance Valuation. Collegium Advisors has a team with extensive professional experience working with clients ranging from governments to privately held and publicly traded corporates to investment firms. The company aims to sustain and develop the quality of its professional workforce and is committed to providing the highest quality of services to its clients.

Collegium Advisors

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Metric
Company Name	Jazz Pharmaceuticals	Acura Pharmaceuticals, Inc.	Collegium Advisors	Cytokinetics, Incorporated
Symbol				CYTK
MSH ID	COM:JAZZPHARMACEUTICALS	COM:ACURAPHARM	COM:COLLEGIUMADVISORS	COM:CYTOKINETICS
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Corporate Finance and Valuation	Healthcare
Industry	Pharmaceuticals	Healthcare & Health Services	Financial Services	Biotechnology
Country	US		NL	US
Stage				Post-IPO Debt
Employee Count		1	11	423
Website	jazzpharmaceuticals.com	acurapharm.com	collegiumadvisors.com	cytokinetics.com
LinkedIn			collegium-advisors	cytokinetics
Founders

Metric
Market Cap	303.61K	6.30B
Enterprise Value
Monthly Web Traffic		7.69K
Web Traffic Growth		0.64
Valuation
Raised Capital		50M

Metric
Revenue				7.53M
Revenue (LTM)
Revenue (NTM)
Gross Profit				-4.36M
EBITDA				-484.31M
Operating Income				-496.20M
Net Income				-526.24M
EPS				-5.45
Diluted EPS				-5.45
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				-28.87
Operating Profit Margin				-65.90
EBITDA Margin				-64.32
Net Profit Margin				-69.64
Return on Equity				1.96
Return on Assets				-0.36
Return on Capital Employed				-0.36

COM:JAZZPHARMACEUTICALS

Jazz Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-14.85
P/B Ratio				-17.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				2.15K
EV Multiple				-9.29

Metric
Days Sales Outstanding				116.72
Days Payables Outstanding				15.73
Days Inventory Outstanding
Operating Cycle				79.39
Cash Conversion Cycle				52.25
Asset Turnover				0.01

Metric
Operating Cash Flow				-414.33M
Free Cash Flow				-415.75M
Cash Flow to Debt				-0.59
Operating Cash Flow/Sales				-55.02
Free Cash Flow Yield				-0.04

Metric
Cash & Equivalents				113.40M
Accounts Receivable				-1.14M
Inventory
Goodwill
Debt to Capitalization				2.65
Debt to Assets				1.01
Current Ratio				7.22
Quick Ratio				10.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				6.06
R&D to Revenue				1.27
SG&A to Revenue				23.48